Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2021-01-15 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
关于核心技术人员离职的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the departure of a core technical personnel from the company Shanghai Medicilon Inc. It details the individual's role, the impact of their departure on the company, the handover of responsibilities, and assurances that the departure will not materially affect the company's operations or ongoing projects. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no mention of shareholder votes or capital changes. The document is a formal announcement about management/staff changes, specifically about a key technical staff member leaving and the company's response. This fits best under the category of Board/Management Information (MANG), which includes announcements of changes in senior management or key personnel. The document length is about 3,038 characters, which is consistent with an announcement rather than a full report. Therefore, the classification is MANG with high confidence.
2021-01-15 Chinese
广发证券股份有限公司关于上海美迪西生物医药股份有限公司核心技术人员离职的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from the sponsor (Guangfa Securities) regarding the departure of a core technical staff member at Shanghai Medicilon Inc. It includes specifics about the individual's role, impact on projects, confidentiality and non-compete agreements, and the company's measures to ensure continuity. The document references regulatory rules related to the STAR Market listing and is a formal verification report by the sponsor. It does not contain financial statements, earnings data, or general regulatory announcements but focuses on a personnel change with an impact assessment. This fits best under Regulatory Filings (RNS) as it is a compliance-related verification report that does not fit other categories like Board/Management Information (MANG) because it concerns a core technical staff member, not board or senior management changes. The document length is under 5,000 characters, but it is not merely an announcement of a report publication; it is the report itself. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-01-15 Chinese
2020年年度业绩预增公告
Earnings Release Classification · 95% confidence The document is titled as an "Annual Performance Forecast Announcement" for the year 2020 by Shanghai Medicilon Inc. It provides preliminary profit estimates and comparisons to the prior year, explicitly stating that the forecast is unaudited and that final audited results will be disclosed in the formal annual report. The document is short (1285 characters) and serves as a performance forecast announcement rather than a full annual report or earnings release. It does not contain actual audited financial statements or detailed financial analysis, but rather a profit guidance and risk disclosure. This fits the profile of an Earnings Release (ER) as it is an initial announcement of periodical financial results with key highlights only, not the full annual report (10-K) or interim report (IR). FY 2020
2021-01-08 Chinese
广发证券股份有限公司关于上海美迪西生物医药股份公司2020年度持续督导现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2020年度持续督导现场检查报告" which translates to "2020 Annual Continuous Supervision On-site Inspection Report" by the sponsoring securities company (广发证券股份有限公司) for the listed company 上海美迪西生物医药股份有限公司. The content details the on-site inspection covering governance, internal controls, information disclosure, independence, related party transactions, use of raised funds, and overall business operations during the 2020 period. It is a detailed report of the sponsor's continuous supervision activities rather than a full annual report or audit report. It is not a brief announcement or a certification letter but a substantive report on the sponsor's inspection findings. This type of document aligns with an Audit Report / Information (AR) category, as it is a standalone report on regulatory compliance and internal controls, not the full annual financial report (10-K) or other categories. The document length (2761 characters) is sufficient for a detailed report but not a full annual report. Therefore, the best classification is AR with high confidence. FY 2020
2020-12-23 Chinese
股东减持股份计划公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a shareholder's plan to reduce their holdings in the company. It details the shareholders involved, their current holdings, the planned reduction amounts, methods, timing, and reasons for the reduction. It references compliance with securities laws and stock exchange rules. There are no financial statements, earnings data, or management discussions. The document is a formal notification of a shareholding change plan by significant shareholders, which fits the definition of a Major Shareholding Notification (MRQ). The document length is 3219 characters, which is typical for such announcements. Therefore, the appropriate classification is MRQ.
2020-12-22 Chinese
关于持股5%以上股东部分股份解除质押的公告
Major Shareholding Notification Classification · 100% confidence The document is a short announcement (680 characters) about a shareholder (Lin Changqing) who holds more than 5% of the company's shares and has released a portion of those shares from pledge. It details the number of shares released from pledge and the remaining pledged shares, with no mention of financial results, management changes, or other report content. This fits the definition of a Major Shareholding Notification (MRQ), as it concerns changes in significant share ownership levels and pledging status. It is not a full report or financial statement, nor an announcement of a report publication. Therefore, the correct classification is MRQ.
2020-12-18 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.